We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks. AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

“ENHERTU is the first HER2 directed option approved for HER2 mutant disease and confirms the relevance of HER2 as a target in lung cancer.” ...

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer Recommendation based on DESTINY-Lung02 trial results, which showed Daiichi Sankyo ...

DURING SCREENING SEASON, which runs from March to December, LUCAS sets off on Mondays from the cancer institute in Morgantown ...

Rates of interstitial lung disease were similar across the ENHERTU followed by THP and the ddAC-THP arms as determined by an independent adjudication committee.

ENHERTU is currently approved in more than 70 countries in the second-line or third-line metastatic setting of HER2 positive gastric cancer based on DESTINY-Gastric01, a randomized phase 2 trial ...

ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...

Interstitial lung disease (ILD) or pneumonitis events occurred in 12.1% of patients treated with ENHERTU plus pertuzumab as determined by an independent adjudication committee.

Doctors said patients with other types of cancer that are HER2 low may also benefit from Enhertu, including patients with gastric, lung, pancreatic and colorectal cancer.